Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SEMA4D
REST API REST API
Homo sapiens
SEMA4D is differentially expressed in 278 experiments: 151 organism parts: liver, bone marrow, ... (149 more);, 233 disease states: normal, control, ... (231 more);, 103 cell types 411 cell lines 24 compound treatments and 68 other conditions.
Synonyms coll-4, SEMAJ, CD100, C9orf164, FLJ39737
Orthologs SEMA4D (Gallus gallus)   Sema4d (Mus musculus)   SEMA4D (Danio rerio)   A5D7C8_BOVIN (Bos taurus)   Sema4d (Rattus norvegicus)   sema4d (Xenopus laevis)   SEMA4D (Canis familiaris)   (Compare orthologs)
InterPro Term Plexin_repeat, Ig_sub, Plexin-like, Immunoglobulin, Ig-like, Ig_sub2, Semaphorin/CD100_Ag
Gene Ontology Term plasma membrane, protein binding, membrane, receptor binding, anti-apoptosis, cell differentiation, cell adhesion, axon guidance, multicellular organismal development, receptor activity, immune response, nervous system development, integral to membrane, positive regulation of axonogenesis
UniProt Accession Q92854, C9JFP1, C9JD54, C9JYS7, E9PFD9, F5H044
Search EB-eye ENSG00000187764
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
T84
2
E-GEOD-1474, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
Jurkat
2
E-MTAB-62, E-MEXP-2197
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
405 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, E-TABM-34, ... (51 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
CD8+ T cell
1
2
E-AFMX-5, E-TABM-145, E-MTAB-25
macrophage
1
2
E-GEOD-3982, E-GEOD-22373, E-GEOD-8286
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-2280, E-GEOD-16363, ... (52 experiments)

Factor Value U/D Experiments
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
neuroblastoma
1
2
E-MTAB-62, E-GEOD-1825, E-MTAB-37
colon carcinoma
1
2
E-MTAB-37, E-GEOD-3726, E-MTAB-62
chronic myelogenous leukemia
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5550
mesothelioma
1
E-MTAB-62
227 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-GEOD-7307, E-GEOD-20719, ... (7 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
CNOT7+CNOT8
1
1
E-MEXP-2218
TGF
1
E-GEOD-15205
mannitol
1
E-GEOD-6400
bacterial endotoxin
1
E-GEOD-3284
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, ... (9 experiments)

Environmental stress
studied in E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-GEOD-20504, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-GEOD-12108

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.366 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM